Clinical Pre-screening Protocol for Ovarian Cancer
- Conditions
- Ovarian Cancer
- Registration Number
- NCT03877796
- Lead Sponsor
- Allarity Therapeutics
- Brief Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 60
- Patients with histological confirmed epithelia ovarian cancer
- Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- FFPE tumor tissue available
- Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug up to 2 years based on FFPE ovarian cancer tissue
- Secondary Outcome Measures
Name Time Method Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer up to 2 years
Trial Locations
- Locations (5)
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
OU Health Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
Swedish Center for Research and Innovation
🇺🇸Seattle, Washington, United States
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, Scotland, United Kingdom
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
🇬🇧London, United Kingdom
Dana-Farber Cancer Institute🇺🇸Boston, Massachusetts, United States